Contents lists available at ScienceDirect



European Journal of Pharmaceutics and Biopharmaceutics

journal homepage: www.elsevier.com/locate/ejpb



Research Paper

Monitoring of multiple solid-state transformations at tablet surfaces using multi-series near-infrared hyperspectral imaging and multivariate curve resolution



Guilherme L. Alexandrino^a, Milad R. Khorasani^b, José M. Amigo^c, Jukka Rantanen^b, Ronei J. Poppi^{a,*}

^a Institute of Chemistry, State University of Campinas – UNICAMP, P.O. Box 6154, 13084-971 Campinas, SP, Brazil

^b Department of Pharmaceutics and Analytical Chemistry, Faculty of Pharmaceutical Sciences, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark ^c Department of Food Science, Faculty of Sciences, University of Copenhagen, Rolighedsvej 30, DK-1958 Frederiksberg C, Denmark

ARTICLE INFO

Article history: Received 31 October 2014 Revised 30 January 2015 Accepted in revised form 30 March 2015 Available online 20 April 2015

Keywords: Piroxicam Lactose Dehydration Solid dosage forms Multi-series hyperspectral imaging MCR-ALS

ABSTRACT

The assessment of the solid-state stability of active pharmaceutical ingredient (API) and/or excipients in solid dosage forms during manufacturing and storage is mandatory for safeguarding quality of the final products. In this work, the solid-state transformations in tablets prepared as blends of piroxicam monohydrate, polyvinylpyrrolidone and the lactose forms monohydrate or anhydrate were studied when the tablets were exposed to the 23–120 °C range. Multi-series near-infrared hyperspectral images were obtained from the surface of each sample for unveiling the local evolution of the solid-state transformations. The preprocessed spectra from the images (dataset) were arranged in augmented matrices, according to the composition of the tablets, and the profile of the overlapped compounds (relative concentration) along the solid-state transformations in the pixels was resolved by using multivariate toxe monohydrates could be mapped separately in the samples (explained variances by the models >96%) even when both compounds were being transformed simultaneously (80–120 °C). The images reproduced the same trends obtained from thermogravimetric analysis of the tablets, with the advantage that the pixel-to-pixel heterogeneity of each compound at the surface of the tablets was highlighted.

© 2015 Elsevier B.V. All rights reserved.

1. Introduction

Solid-state transitions during manufacturing of pharmaceuticals are relevant concerns for the industry. The addition/removal of the water of crystallization in critical unit operations (e.g. crystallization, wet granulation, drying, pelletization) or during storage may induce the coexistence of distinct hydrate/anhydrate forms of active pharmaceutical ingredients (APIs) and/or excipients [1]. Crystal hydrates have particular physicochemical properties compared with their anhydrate counterparts that may result in varying solubility and dissolution behavior [2–4]. Therefore, the drug bioavailability may be seriously affected and may compromise the quality of the final product due to undesirable mixtures of different polymorphs [5–7].

Piroxicam (PRX) is a non-steroidal and anti-inflammatory drug that exists at least in three different anhydrate polymorphs (forms I, II and III) and one monohydrate form, with each of them having distinct Raman and NIR spectra [8]. The success on employing

* Corresponding author. E-mail address: ronei@iqm.unicamp.br (R.J. Poppi). spectroscopic techniques for monitoring solid-state transformations in pharmaceutical solid dosage forms (SDFs) has already been explored with the applicability of near-infrared, Raman [9,10] and Terahertz [11] spectroscopies for studying hydrate/anhydrate transformations in drug hydrates in different conditions. Although conventional single point spectroscopy was capable to detect solid-state transformations in the SDFs along their thermal conditioning, only bulk chemical information of the samples could be obtained. Therefore, the use of hyperspectral imaging (HSI) for solid-state monitoring can be extremely beneficial due to the possibility of unveiling the intensity of the chemical transitions in the sample in which the blend heterogeneity aspects are also being considered.

In HSI the region of interest (ROI) at the surface of a SDF is split in adjustable regular subspaces, denominated pixels that contain their own spectrum. The pixel sizes cannot be lower than few micrometers due to the inherent decreasing of the spectral signal-to-noise ratio even in the modern NIR-microscopes. The data are sorted in a x,y,z array, wherein xy coordinates define the positions of the pixels in the mapped ROI and the spectral variables (λ) are disposed in the z coordinates. The hypercube obtained is

Polyvinylpyrrolidone K30 (MW 40,000 g mol⁻¹, water $\leq 5.0\%$) and α -lactose monohydrate \geq 99% were obtained from Sigma–Aldrich (St. Louis, MO, USA). Lactose anhydrate (Pharmatose DCL 21, P.A. grade) was provided by Nomeco A/S (Copenhagen, Denmark).

2.2. Preparation of piroxicam monohydrate

The drug monohydrate form was prepared by dispersing approximately 2.0 g of PRX-AH in 100 ml of deionized water, keeping the dispersion stirring for 72 h at room temperature. Then the PRX-MH (yellow solid) was vacuum-filtered and transferred to a petri dish for drying in ambient conditions during 48 h. The total conversion of the drug to the monohydrate form was confirmed by X-ray powder diffraction analysis (XRPD), Fig. 1 [21]. The XRPD diffractograms were obtained using a PANalytical X'Pert Pro diffractometer in Bragg-Brentano geometry with a PIXcel detector (PANalytical B.V., Almelo, the Netherlands). The radiation was a continuous 2θ scan with non-monochromatic Cu K α_1 (λ = 1.5406, 40 mA and 45 kV) in the range 5–35° and point resolution of 0.026°.

2.3. Preparation of the tablets

Tablets were prepared from PRX-MH, PVP and one of the lactose forms: LAC-AH or LAC-MH. Six different formulations of tablets varying the proportions of the drug and excipients (Table 1) were dry blended and compacted using an evaluable dye (13 mm diameter) in a manual hydraulic press (PerkinElmer, Waltham, MA, USA) at 5.5 kN. Pure-reference compacts of PRX-AH and from each of the above-mentioned compounds were prepared likewise.

2.4. Acquisition of the hyperspectral images

Hyperspectral images were acquired in the reflectance mode with the Headwall photonics spectrometer (model 1002A-00371) containing a prototype hyperspectral camera kindly provided by FOSS A/S (Hillerød, Denmark), working in the wavelength range of 1000–1700 nm and spectral resolution of 7 nm (total of 142 variables per spectrum). The spectrometer was adapted to a line mapping configuration with pixel dimensions of $250 \times 50 \,\mu\text{m}^2$. The mapped area $(80 \times 40 \text{ mm}^2)$ included the entire surface of the tablets. Each image was acquired in approximately 5 min, using a non-commercial software provided by the company.

In this work, a methodology using NIR-HSI and chemometrics was developed for studying the dehydration of tablets containing the model drug piroxicam monohydrate (PRX-MH) and the excipients polyvinylpyrrolidone (PVP) and one of the lactose forms: α -lactose (LAC-AH) or lactose monohydrate (LAC-MH). Tablets varying the proportions of the ingredients were conditioned in a temperature-controlled oven within the range 23-120 °C, and multi-series images were acquired for each sample along the experiment. The processing of the HSI-NIR data using MCR-ALS revealed the profiles of all the compounds during the solid-state transformations in the pixels over the surface of the tablets at different temperatures. The similarities between the trends obtained from the HSI-NIR results and thermogravimetric analysis of the tablets highlighted the potential applicability of NIR-imaging spectroscopy for monitoring dehydration of API and excipients in pharmaceutical SDFs.

2. Experimental

2.1. Materials

Piroxicam anhydrate (P.A. grade) was obtained from Christian Olsen Pharmaceuticals A/S (Gentofte, Denmark).

generally unfolded into a matrix $(xy \times \lambda)$ for obtaining chemical information, through the selection of specific wavelengths [12] or

by using chemometrics. In HSI-NIR, the highly overlapped bands

usually require multivariate data analysis for extracting chemical

information in the pixels [13–15]. Thus, principal components analysis (PCA) can be explored for a qualitative interpretation of

the images. However, the lack of chemical selectivity in the pixels leads to principal components (PCs) that are describing mixed

combination of effects in the sample, thus hampering the exclu-

sively chemical interpretation of the images. Multivariate curve

resolution (MCR) methods overcome this drawback by using itera-

tive algorithms (e.g. alternating least squares - ALS) that optimize

the resolution of each chemical compound separately in the

images. MCR-ALS algorithm is based in the Lambert-Beer law, in

which a spectrum from a mixture is considered a sum of the spec-

tra from the corresponding pure-reference compounds weighted

by their respective relative concentrations. In image analysis, the

spectra of the pixels arranged in the data matrix $\mathbf{D}_{(\mathbf{x}\mathbf{y}\times\lambda)}$ are

resolved with MCR-ALS in the new matrices $\mathbf{C}_{(xy \times n)}$ (relative con-

centration of the **n** compounds in the pixels), **S** (ALS-resolved

pure-reference spectra) and **E** (experimental errors) according to the eq. $\mathbf{D} = \mathbf{CS}^{T} + \mathbf{E}$. The refolding of **C** according to the original posi-

tion of the pixels results in chemical images expressing the distribution of the resolved compounds on the ROI of the corresponding

sample [16–18]. The ALS-optimization of **S** results that minor spec-

tral changes due to chemical interactions among the compounds

and from physical variability due to scattering effects (that can still

be present in the data even after preprocessing) may be handled

during the resolution, representing the main advantage of this

algorithm for the analysis of spectral data from pharmaceutics

[19]. A relevant drawback of MCR methods is on modeling rank-deficient matrices, i.e. when the profiles of distinct compounds are linearly correlated in all the pixels, resulting in a number of

resolved compounds lower than the true number of chemical compounds in the samples. A common strategy for resolving rank-

deficient matrices in HSI analysis is the use of augmented arrays.

incorporating the unfolded images from similar samples, but

differing on the concentrations of the compounds, in a unique

column-wise augmented matrix (DAUG). The extra addition of

unfolded pure-reference images in **D**_{AUG} and the use of the corre-

spondence among species constraint (i.e. by informing the algorithm

the pixels of D_{AUG} where the concentration of the compounds is

known a priori) minimize the rank-deficiency originally presented

in **D**, and each compound can be resolved successfully [20].



Fig. 1. XRPD patterns of PRX-AH and the PRX-MH prepared according to Section 2.2.

Download English Version:

https://daneshyari.com/en/article/8413725

Download Persian Version:

https://daneshyari.com/article/8413725

Daneshyari.com